Literature DB >> 8389393

Interlobar variation in the recovery of bronchoalveolar lavage fluid, cell populations, and angiotensin-converting enzyme in normal volunteers.

A H Limper1, U Specks, W M Brutinel, W J Martin, M S Rohrbach.   

Abstract

Although bronchoalveolar lavage (BAL) is useful in studying a variety of lung diseases, it results in substantial dilution of cells and soluble proteins recovered from the lower respiratory tract. Surprisingly little is known about regional differences in BAL recovery in normals and patients with lung disorders. In order to assess regional differences in BAL in normals, we performed a prospective study of BAL in twenty non-smoking volunteers. With the subjects supine, BAL was performed in the right middle lobe (RML), right lower lobe (RLL) and Lingula (LING). The volumes recovered, cell numbers, and angiotensin converting enzyme (ACE) activities were determined separately for each BAL site. ACE was chosen as a representative soluble protein found in the lower respiratory tract which was easily measured in the BAL of normals. BAL volumes recovered from the RLL were significantly smaller than from the RML or LING, perhaps related to the dependent location of the RLL (P = 0.0002). The concentration of ACE and cells recovered per ml of BAL were significantly greater in the RLL than either the RML or LING (P = 0.05). In contrast, the total numbers of cells and total ACE recovered were similar from all sites sampled. This suggests that the differences in measured concentrations were due to different fluid recovery from these sites, resulting in variable dilution of proteins and cells. Urea measurement has been proposed as a means to quantify the epithelial lining fluid (ELF) volume sampled by BAL and estimate the actual concentrations of proteins present in the lower respiratory tract (J Appl Physiol 1986; 60:532-538).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389393

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

1.  Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.

Authors:  J E Conte; J A Golden; M McQuitty; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity.

Authors:  J A Ribes; A H Limper; M J Espy; T F Smith
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

3.  The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung.

Authors:  A H Limper; J S Hoyte; J E Standing
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

4.  Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity.

Authors:  John W Wilson; Andew H Limper; Thomas E Grys; Theresa Karre; Nancy L Wengenack; Matthew J Binnicker
Journal:  Diagn Microbiol Infect Dis       Date:  2011-02       Impact factor: 2.803

5.  Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages.

Authors:  D M O'Riordan; J E Standing; K Y Kwon; D Chang; E C Crouch; A H Limper
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.

Authors:  J E Conte; J A Golden; S Duncan; E McKenna; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Proteomic analysis of human bronchoalveolar lavage fluid after subsgemental exposure.

Authors:  Matthew W Foster; J Will Thompson; Loretta G Que; Ivana V Yang; David A Schwartz; M Arthur Moseley; Harvey E Marshall
Journal:  J Proteome Res       Date:  2013-04-24       Impact factor: 4.466

8.  Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages.

Authors:  Suk-Joong Yong; Zvezdana Vuk-Pavlovic; Joseph E Standing; Erika C Crouch; Andrew H Limper
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.